STAR-001
Glioblastoma, Brain Metastases, Pediatric CNS Cancers
Phase 1b/2 (planned)Active
Key Facts
Indication
Glioblastoma, Brain Metastases, Pediatric CNS Cancers
Phase
Phase 1b/2 (planned)
Status
Active
Company
About Starlight Therapeutics
Starlight Therapeutics is an AI-driven biotech subsidiary of Lantern Pharma, singularly focused on addressing the high unmet need in CNS cancers. Its lead asset, STAR-001, is a small molecule drug candidate with orphan and rare pediatric disease designations, demonstrating promising preclinical data including excellent blood-brain barrier penetration and nanomolar potency. The company is preparing to initiate Phase 1b/2 clinical trials in multiple adult and pediatric indications following the completion of a Phase 1a safety study, positioning it in a multi-billion dollar market with limited effective therapies.
View full company profile